What is CEL-SCI?
Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI operates at the intersection of oncology and immunology. The firm is primarily engaged in the rigorous research and development of proprietary immunotherapy products designed to address complex health challenges, including various forms of cancer, autoimmune disorders, and infectious diseases. With over four decades of operational history, the company has transitioned from a nascent research entity into a specialized developer of clinical-stage treatments, maintaining a focus on high-impact medical solutions that address significant unmet patient needs in the global healthcare market.
How much funding has CEL-SCI raised?
CEL-SCI has raised a total of $53.5M across 3 funding rounds:
Stock Offering
$14.7M
Stock Offering
$31.7M
Stock/Share Issuance
$7.2M
Stock Issuance/Offering (2020): $14.7M with participation from Undisclosed
Stock Issuance/Offering (2021): $31.7M, investors not publicly disclosed
Stock/Share Issuance (2026): $7.2M, investors not publicly disclosed
Key Investors in CEL-SCI
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for CEL-SCI?
With the successful completion of this major enterprise-level funding round, CEL-SCI is positioned to accelerate its clinical development programs. The strategic allocation of these resources will likely prioritize the advancement of its lead immunotherapy candidates through critical regulatory milestones and late-stage clinical trials. As the company navigates the complexities of the biotech regulatory environment, this financial backing provides the necessary runway to scale operations and potentially bring transformative treatments to market. Investors and stakeholders will be closely monitoring the firm's ability to translate this capital into tangible clinical outcomes and long-term value creation within the immunotherapy space.
See full CEL-SCI company page
